Artigo
Leitura de 6 m
9 de setembro de 2026
SAÚDE COMUNITÁRIA E GLOBAL
{{cartTotalQuantity}}
Menu Diagnóstico molecular
Instrumentos e software
Soluções da Cepheid
Testagem em qualquer lugar
Gestão da utilização de antibióticos
Cepheid’s Insights
Webinars
Cepheid RADAR
Support Center
Documents & Technical Resources
Contacte-nos
Acerca da Cepheid
Missão e histórica
A nossa liderança
Eventos
Distribuidores
Oportunidades de desenvolvimento de negócio
Inovar com a Cepheid
Conheça a motorizada Cepheid
Notícias
Carreiras
WHO EUL
Xpert® Hemorrhagic Fever Panel
When Clarity Matters Most.
Rapid Answers. Confident Action. No Compromise.
WHO EUL only. Poderá não estar disponível em todos os países.
A necessidade
A solução
O impacto
Rapidly identify patients with suspected viral hemorrhagic fever
Support timely infection control and outbreak response
1. CDC. Screening and Evaluating an Ill Person for Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/diagnosis-testing/index.html
2. CDC. Infection Prevention and Control for Patients with Suspected or Confirmed Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/index.html [ecdc.europa.eu]
3. OMS. Lassa Fever Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/lassa-fever [ijprems.com]
4. CDC. Lassa Fever Fact Sheet. https://stacks.cdc.gov/view/cdc/12236/cdc_12236_DS1.pdf [cdc.gov]
5. World Health Organization. Marburg virus disease - Equatorial Guinea and the United Republic of Tanzania. Disease Outbreak News, 8 de maio de 2023. [who.int]
6. Centers for Disease Control and Prevention (CDC). History of Marburg Outbreaks. Updated 2025. [cdc.gov]
7. World Health Organization. Crimean-Congo hemorrhagic fever: Fact Sheet. Updated 20 de fevereiro de 2025. [who.int]
8. UK Health Security Agency. Crimean-Congo hemorrhagic fever: origins, reservoirs, transmission and guidelines. Updated 2025. [gov.uk]
Xpert Hemorrhagic Fever Panel:
9. FDA 510(k) Decision Summary, Xpert® Hemorrhagic Fever Panel (K253653). Inactivation study results demonstrating viral inactivation during sample preparation are described in the submission documentation (see p. 23). Disponível em: https://www.accessdata.fda.gov/cdrh_docs/reviews/K253653.pdf.
1. CDC. Screening and Evaluating an Ill Person for Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/diagnosis-testing/index.html
2. CDC. Infection Prevention and Control for Patients with Suspected or Confirmed Viral Hemorrhagic Fevers. https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/index.html [ecdc.europa.eu]
Ficha técnica
ENG
MSDS/FDS
ENG
MSDS/FDS
FRANCÊS
Folheto informativo
ENG
Cartridge Preparation
ENG
Artigo
Leitura de 6 m
9 de setembro de 2026
SAÚDE COMUNITÁRIA E GLOBAL
Artigo
Leitura de 5 m
12 de junho de 2026
SAÚDE COMUNITÁRIA E GLOBAL